期刊
PANCREAS
卷 49, 期 1, 页码 62-75出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MPA.0000000000001455
关键词
irinotecan liposomal injection; mPAC; pancreatic cancer; phase 3 clinical trial; subanalysis; post hoc
资金
- Novartis
- Pfizer
- Merck Serono
- Polaris
- TTY
- SyncoreBio
- Celgene
- 4SC
- Bristol Myers-Squibb
- Roche
- Amgen
- AstraZeneca
- Bayer
- Merrimack
- Medimmune
- Sanofi
- Newlink Genetics
- Precision Therapeutics
- Aduro Biotech
- EMD Serono
- Halozyme
- Oncomed
- CTI
- Lilly
- Abbvie
- Plexxikon
- Verastem
- Merck
- BioMedVally Discoveries
- Merrimack Pharmaceuticals, Inc, Cambridge, MA
- Shire
Objectives The NAnoliPOsomaL Irinotecan (NAPOLI-1) study (NCT01494506) was the largest global phase 3 study in a post-gemcitabine metastatic pancreatic adenocarcinoma (mPAC) population (N = 417). The subanalyses reported here investigated the prognostic effect of tumor characteristics and disease stage, prior treatment characteristics, baseline patient characteristics on survival outcomes in NAPOLI-1, and whether liposomal irinotecan (nal-IRI) + 5-fluorouracil/leucovorin (5-FU/LV) benefited patients with mPAC across subgroups. Methods Post hoc analyses were performed in the NAPOLI-1 population (4 across tumor characteristics and disease stage, 6 across prior treatment characteristics, and 4 across patient baseline characteristics). Survival outcomes were estimated by Kaplan-Meier analysis and patient safety data were evaluated. Results Mortality and morbidity risk was lower on nal-IRI+5-FU/LV treatment across subgroups. Exceptions were patients who had received prior nonliposomal irinotecan and those who had undergone prior Whipple procedure (overall survival hazard ratio = 1.25 and 1.23, respectively). Decreased appetite, liver metastases, and number of measurable metastatic lesions seemed to be prognostic of survival in this population. Subgroup safety data were generally comparable with those in the overall NAPOLI-1 safety population. Conclusions A diverse population of patients with mPAC that progressed on gemcitabine-based therapy benefited from nal-IRI+5-FU/LV versus 5-FU/LV, potentially helping guide treatment decisions for challenging cases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据